NCT00824655View on ClinicalTrials.gov

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Pneumococcal Vaccines
Interventions
BIOLOGICAL

13vPnC

13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.

BIOLOGICAL

13vPnC

13vPnC will be administered by intramuscular injection at approximately 12 months of age.

Trial Locations (7)

SE-63188

Pfizer Investigational Site, Eskilstuna

SE-40014

Pfizer Investigational Site, Gothenburg

SE-20502

Pfizer Investigational Site, Malmo

SE-70185

Pfizer Investigational Site, Örebro

SE-83183

Pfizer Investigational Site, Östersund

SE-45180

Pfizer Investigational Site, Uddevalla

SE-90185

Pfizer Investigational Site, Umeå

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY